Hormonal
Tirzepatide promotes significant body weight loss in non-diabetic adults with obesity, with efficacy increasing with dose (5, 10, 15 mg).
For individuals with obesity who do not have Type 2 Diabetes, Tirzepatide is an approved once-weekly injection that has been shown to produce significant and clinically meaningful weight loss over 72 weeks. The medication is titrated starting at 2.5 mg and increased to 5, 10, or 15 mg weekly. It also improves blood pressure, waist circumference, and lipid profiles.
The SURMOUNT-1 study was a clinical trial of 72 weeks performed in 2539 obese patients without T2D that were randomized in four arms with placebo or TZP at the dose of 5mg,10 mg or 15 mg... TZP treatment was correlated with reduced systolic blood pressure (SBP), waist circumference, plasma lipid concentrations and fasting insulin
Why this rating
Based on large-scale, randomized, controlled Phase 3 clinical trials (SURMOUNT-1, 2, 3, 4).
Source
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Salvatore Corrao et al. · Frontiers in Endocrinology · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →